Dianthus Therapeutics Ownership | Who Owns Dianthus Therapeutics?
Dianthus Therapeutics Ownership Summary
Dianthus Therapeutics is owned by 16.64% institutional investors, 0.13% insiders, and 83.23% retail investors. Fmr is the largest institutional shareholder, holding 20.55% of DNTH shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.86% of its assets in Dianthus Therapeutics shares.
DNTH Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Dianthus Therapeutics | 16.64% | 0.13% | 83.23% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 7.77M | 20.55% | $651.86M |
| Blackrock funding, inc. /de | 3.18M | 8.40% | $266.50M |
| Ra capital management | 2.61M | 6.91% | $219.18M |
| Wellington management group llp | 2.60M | 6.87% | $217.84M |
| Fairmount funds management | 2.54M | 6.71% | $212.92M |
| Avidity partners management lp | 2.10M | 5.57% | $184.75M |
| Vanguard group | 2.05M | 5.42% | $84.42M |
| Octagon capital advisors lp | 1.95M | 5.15% | $163.36M |
| Tcg crossover management | 1.68M | 4.44% | $140.70M |
| Citadel advisors | 1.61M | 4.26% | $135.15M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Avidity partners management lp | 2.10M | 41.81% | $184.75M |
| Octagon capital advisors lp | 1.95M | 18.08% | $163.36M |
| Fairmount funds management | 2.54M | 15.38% | $212.92M |
| Catalio capital management, lp | 560.31K | 9.82% | $47.02M |
| Silverarc capital management | 654.75K | 5.61% | $54.95M |
| 5am venture management | 365.05K | 5.26% | $14.36M |
| Sio capital management | 370.05K | 4.45% | $31.05M |
| Tcg crossover management | 1.68M | 4.03% | $140.70M |
| Cormorant asset management, lp | 950.00K | 4.00% | $79.72M |
| Vr adviser | 1.18M | 3.70% | $99.03M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 7.77M | 0.03% | 1.34M |
| T. rowe price investment management | 1.29M | 0.07% | 1.29M |
| Blackrock funding, inc. /de | 3.18M | 0.00% | 1.26M |
| Fred alger management | 1.16M | 0.43% | 1.13M |
| Deerfield management company, l.p. (series c) | 1.02M | 1.01% | 1.02M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Deep track capital, lp | - | - | -2.23M |
| Vestal point capital, lp | 1.18M | 2.10% | -2.02M |
| Marshall wace, llp | 341.93K | 0.03% | -666.60K |
| 5am venture management | 365.05K | 5.26% | -619.67K |
| Point72 asset management | 643.60K | 0.07% | -522.49K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| T. rowe price investment management | 1.29M | 0.07% | 1.29M | $108.44M |
| Deerfield management company, l.p. (series c) | 1.02M | 1.01% | 1.02M | $85.58M |
| Cormorant asset management, lp | 950.00K | 4.00% | 950.00K | $79.72M |
| Farallon capital management | 836.00K | 0.40% | 836.00K | $70.16M |
| Jennison associates | 485.14K | 0.03% | 485.14K | $40.71M |
Sold Out
| Holder | Change |
|---|---|
| Montag a & associates | -9.00 |
| Creative financial designs inc /adv | -10.00 |
| Principal securities | -11.00 |
| Corecap advisors | -11.00 |
| Td private client wealth | -17.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 77 | -54.44% | 6,290,279 | -87.19% | 16 | 0.10% | 62 | -48.33% | 14 | -51.72% |
| Dec 31, 2025 | 22 | -85.23% | 2,846,620 | -93.92% | 7 | 0.04% | 15 | -84.38% | 6 | -82.35% |
| Sep 30, 2025 | 34 | -67.31% | 2,900,005 | -92.58% | 8 | 0.07% | 22 | -54.17% | 7 | -82.05% |
| Jun 30, 2025 | 104 | 1.96% | 39,106,737 | 3.69% | 109 | 0.90% | 48 | - | 39 | 34.48% |
| Mar 31, 2025 | 12 | -87.23% | 14,988,897 | -56.30% | 43 | 0.44% | 5 | -90.74% | 3 | -86.36% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 2.11M | 3.86% | 435.55K |
| Vanguard Total Stock Mkt Idx Inv | 1.57M | 2.88% | 4.26K |
| Fidelity Growth Company Fund | 1.51M | 2.77% | 328.08K |
| Vanguard Health Care Inv | 1.46M | 2.68% | -114.23K |
| Polar Capital Biotech S Inc | 1.02M | 1.86% | - |
| iShares Russell 2000 ETF | 843.58K | 1.55% | 7.10K |
| Fidelity Advisor Biotechnology I | 730.06K | 1.34% | - |
| State Street® SPDR® S&P® Biotech ETF | 655.76K | 1.20% | -4.66K |
| T. Rowe Price US Small-Cap Core Equity | 499.30K | 0.91% | 499.30K |
| T. Rowe Price Small-Cap Stock | 499.30K | 0.91% | 499.30K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 01, 2026 | Randhawa Simrat | EVP, Head of R&D | Sell | $380.01K |
| Jun 01, 2026 | Randhawa Simrat | EVP, Head of R&D | Sell | $1.54M |
| Jun 01, 2026 | Randhawa Simrat | EVP, Head of R&D | Sell | $487.00K |
| May 08, 2026 | Soteropoulos Paula | - | Sell | $51.20K |
| Apr 09, 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | $738.84K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 5 |
| 2026 Q1 | - | 21 |
| 2025 Q4 | - | 5 |
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | - |
DNTH Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools